EMA denies adaptive licensing project 'slowing or closing down'; calls for more applications
This article was originally published in SRA
The European Medicines Agency said yesterday it wanted to quash a rumor that its in-demand adaptive licensing pilot project was slowing or closing down. "We are very much open to further submissions" from drug companies that want to take part in the initiative, a UK regulator involved in the pilot said.
You may also be interested in...
Drug companies have their last chance to negotiate which documents and information Italy’s regulator, AIFA, will be entitled to request of them when they submit pricing and reimbursement applications.
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.
New medicines under evaluation at the European Medicines Agency.